泰格醫藥(03347.HK)上半年淨利潤4.93億元 同比減少64.50%
格隆匯8月28日丨泰格醫藥(03347.HK)公佈中期業績,2024年上半年,公司營業收入為33.58億元,同比減少9.5%;歸屬於上市公司股東的淨利潤4.93億元,同比減少64.50%;基本每股收益為0.57元。
2024年上半年,實現主營業務收入32.96億元,同比下降10.21%。其中,臨牀試驗技術服務收入16.37億元,同比下降22.17%;臨牀試驗相關及實驗室服務收入16.59億元,同比增長5.84%。
從地域角度,公司境內主營業務收入18.22億元,同比下降11.48%,境內收入下降主要由於2024年上半年臨牀試驗技術服務板塊境內收入同比下滑,具體原因於按板塊分析中詳述。公司境外主營業務收入14.74億元,同比下降8.58%;去年同期,公司產生了部分特定疫苗項目相關收入,剔除該等項目後公司的境外收入同比實現了增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.